For research teamsFind studies
Back to all studies
CompletedNCT02286817

Phase I Single Dose, Open-Label Pharmacokinetic Study and Single-Blind, Placebo-Controlled Dose Escalation Study of NFC-1 in Adolescents With Attention-Deficit Hyperactivity Disorder

This study is completed. It focuses on ADHD and currently lists study information in the United States.

ADHDOtherFrom 12 Years to 17 Years
In plain English

Key information made simple

This study exists to better understand the safety of the medication NFC-1 and how manageable it feels in practice. Researchers are trying to understand how people respond to the medication NFC-1 in practice and what may need to be adjusted. For people living with ADHD, the gap between what sounds good on paper and what works in daily life is often important. If the findings are useful, they could help future care become more targeted, practical, and easier to trust. Taking part helps build the evidence that can improve understanding and care for others over time.

What to expect

Your next step

The official record suggests in-person participation through a hospital, with sites including Thomas Jefferson University, Clinical Research Unit in Philadelphia. Participation appears to involve a study treatment together with follow-up visits and routine safety or progress checks. The main fit is usually matching the main diagnosis and having access to the required digital tools, while common reasons not to take part include major medical issues that could make participation unsuitable and pregnancy or breastfeeding. This is an early-stage study, which usually means a smaller group and a focus on learning how the approach behaves.

Official source

Registry reference

This page links back to the public source record so people can verify details directly with the registry and research team.

If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.

Open source record
Need help deciding?

Ask HopeStage to review this study with me

This form records your interest so HopeStage can follow up with practical guidance. It is not a medical eligibility decision and it does not guarantee a study spot.

Loading the security check...
Study reference: NCT02286817. We only ask for your email here. HopeStage can help you review the study, but this is not a medical eligibility decision.
In practice

For you

Taking part may give access to a new approach being evaluated.

It requires regular visits and structured follow-up.

Requires travel, with in-person participation in United States.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

Study clarity

Things to check before joining

Sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Sponsor type
Pharmaceutical company
Main activity
digital app or tool
Time commitment
long follow-up or multiple visits
Study phase
Not available
Enrollment
Not available
Recruitment status
Completed
Source
Official registry link
FAQ

Questions about this study

What is Phase I Single Dose, Open-Label Pharmacokinetic Study and Single-Blind, Placebo-Controlled Dose Escalation Study of NFC-1 in Adolescents With Attention-Deficit Hyperactivity Disorder?

This study is exploring digital app or tool for people with adhd. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed.

Who is behind this study, and what type of sponsor is it?

This study is sponsored by Aevi Genomic Medicine, LLC, a Cerecor company. Based on the sponsor name or official registry information, it appears to be a pharmaceutical company. You should verify the details in the official registry record.

What does participation involve, what phase is it, and what should I ask about safety?

This study may involve digital app or tool, study visits, and assessments. The time commitment is long follow-up or multiple visits. The study phase is not available in HopeStage data. Check the official source record to see whether a phase is listed. Enrollment is not available in HopeStage data. HopeStage cannot say whether a study is safe or right for you. Before joining, ask the research team about possible risks, time commitment, visits, side effects, compensation, safety monitoring, and whether participation may affect your current care.

Where can I verify the study details?

Use the official source record linked on this page to check the full study description, recruitment status, eligibility criteria, locations, sponsor information, phase, enrollment, contact details, and any listed risks or requirements.

Related studies

Other studies you may want to explore next